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See Article, pages 36–41Fibrosis, the hallmark of chronic liver diseases, is one
of the major deleterious processes associated with
chronic hepatitis C. Staging of ﬁbrosis relies on an eval-
uation of several histological features including assess-
ment of extent of the extracellular matrix deposit, the
localization of the deposits within the liver lobule and
changes in lobular architecture. These features are then
integrated into a semiquantitative scoring system. Histo-
logical staging of ﬁbrosis has gained acceptance as a
major element in evaluation of liver damage in hepatitis
C. Indeed, staging mirrors the natural evolution of
chronic hepatitis, predicts evolution toward develop-
ment of cirrhosis and end-stage liver complications, con-
tributes to predicting a sustained response to antiviral
treatment. This is crucial as cirrhosis, the end-point of
ﬁbrosis, is the main cause of morbidity and mortality
in chronic liver diseases [1–4].
Because ﬁbrosis implies morphological damage, liver
biopsy has come to be the natural gold standard for
staging the disease. However, the high prevalence of
chronic hepatitis C in addition to the cost and con-
straints generated by this procedure has triggered an
intensive search for alternative methods for staging the
disease. How to evaluate the performance of these sur-
rogates and how the inherent limits of the biopsy inﬂu-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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discussed in this issue of the Journal by Mehta and col-
leagues [5]. This is a relevant question since liver biopsy
carries potential limitations including sampling errors
and interobserver variations [6,7]. Although several
means exist for minimizing these risks such as procure-
ment of biopsies of suﬃcient length [8] and interpreta-
tion of biopsies by experienced liver pathologists [9],
staging of ﬁbrosis with biopsy will always carry a risk,
albeit low, of misclassiﬁcation thus making the term
‘‘best” standard more appropriate than ‘‘gold” standard
for liver biopsy.
The performance of any surrogates is classically eval-
uated by calculation of the area under the receiver oper-
ating characteristic curve (AUROC) using liver biopsy
as the reference. In this setting, the AUROC represents
the probability that a surrogate will correctly rank two
randomly chosen patients, one with a liver biopsy con-
sidered ‘‘normal” and the other ‘‘diseased”. Because
liver biopsy is not the gold standard but is the best avail-
able standard, a perfect surrogate will never reach max-
imal value (i.e. 1). Taking into account a range of
accuracies of the biopsy and a range of prevalences of
signiﬁcant disease (that inﬂuence the AUROC), Metha
et al. demonstrate that in the most favorable scenario,
an AUROC > 0.90 cannot be achieved when assessing
the so-called ‘‘signiﬁcant ﬁbrosis” even for a perfect
marker [5]. This is important for several reasons. First,
studies have already shown that these maximal AUROC
values have been reached for surrogates, especially when
assessing cirrhosis versus non-cirrhosis, suggesting that
these surrogates may be at least as good as liver biopsy
in the diagnosis of cirrhosis [10]. Second, Metha et al.Published by Elsevier B.V. All rights reserved.
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mance of surrogate markers would employ a clinical
end-point rather than biopsy as gold standard. These
conclusions should be discussed in further detail before
accepting them deﬁnitively.
The main alternatives to liver biopsy that have been
developed in the past 10 years are based on two very dif-
ferent concepts: serum markers and liver stiﬀness [11].
They diﬀer substantially both in their rationale and in
their conception.
Stiﬀness, as assessed by ultrasound (Fibroscan) and
more recently by MRI, evaluates the velocity of propa-
gation of a shock wave within the liver tissue. This
method examines a physical parameter of liver tissue
which is related to its elasticity. Thus, liver biopsy is
used to choose the best discriminative thresholds to pre-
dict histological stage. The main drawback is that addi-
tional space-occupying lesions often encountered in
hepatitis C such as steatosis, edema and inﬂammation
will develop within an organ wrapped in a distensible
but non-elastic envelope (Glisson’s capsula), contribute
to modifying liver texture and may act as a confounding
factors when stiﬀness is concerned. Nevertheless, there
exist strong arguments supporting the hypothesis that
elasticity parallels staging at precirrhotic or cirrhotic
stages. A recent meta-analysis showed that the AUROC
reaches the ‘‘holy grail” of 0.90 for diagnosis of cirrhosis
with Fibroscan [8]. However, it is noteworthy that
changing the deﬁnition of ‘‘diseased” liver from F4 to
F3F4 or F2F3F4 is associated with a progressive
decrease in the AUROC, suggesting that this approach
is valid for diagnosis of cirrhosis but less adequate when
assessing transition from one stage to the upper one, a
crucial goal for treatment decision or patient follow-
up. In this setting, the proposal of a clinical reference
(liver-related death, end-stage liver complications) for
comparing the performances of Fibroscan and biopsy
for diagnosis of cirrhosis is meaningful and seems feasi-
ble. In the mean time, assessing the prognostic value of
the wide range of stiﬀnesses observed within cirrhotic
livers should be useful since this would overcome one
major limitation of the biopsy (i.e. one histological stage
for all type of cirrhosis).
Validation of surrogates compared to a reference
other than biopsy is completely diﬀerent when address-
ing serum markers. Serum markers are combinations
of several blood parameters that are optimized to mirror
the stage of liver ﬁbrosis. Despite the wide number of
proposed combinations, they are all designed in the
same way: they are meant to optimize the choice of
blood parameters and to maximize the algorithm to
match histological stages as assessed using liver biopsy.
This is a fundamental diﬀerence compared to Fibroscan.
While Fibroscan assesses one genuine characteristic of
liver tissue, serum marker algorithm is built to mimicbiopsy irrespective of the biopsy accuracy. In that case,
the ﬁndings presented by Mehta et al. will hold only if
biopsy and serum marker misclassiﬁcations are not cor-
related at any given stage of ﬁbrosis – a challenging
hypothesis. Otherwise, since biopsy was used for choos-
ing the optimal combination of serum markers, a perfect
serum marker could theoretically reach an AUROC of
1.0 and a lower AUROC value is related to serum mar-
ker own limitations rather to limitation of biopsy for
assessing ﬁbrosis.
One major limitation of any of these surrogates lies in
their conception and/or their validation using a dichot-
omized approach (signiﬁcant versus non-signiﬁcant
ﬁbrosis). In addition to the question of what is consid-
ered to be ‘‘signiﬁcant” ﬁbrosis, a deﬁnition which is
variable according to the study and aims pursued, stag-
ing ﬁbrosis cannot be summed up by such a binary
approach. Histological staging systems comprise 5
(METAVIR) or even 7 (Ishak score) diﬀerent stages
[7,12]. This level of complexity has been shown to be rel-
evant not only for individual assessment and follow-up
of disease evolution, but also for deﬁning the rate of
ﬁbrosis progression and the right moment for using anti-
viral therapy or starting prevention of complications
from cirrhosis. The dichotomized approach used for sur-
rogates is imposed by the use of AUROC that tests a
binary hypothesis. Using this approach there is a signif-
icant loss of information and a dependency on the pro-
portion of each stage of ﬁbrosis in the study sample.
Other accuracy measures designed for ordinal gold stan-
dard have recently been published and should overcome
these limitations [13]. However in most works these lim-
itations have been bypassed by considering the diﬀerent
histological stages as linear variables and extrapolating
intermediate values for each of the stages. However, this
is an erroneous supposition since scores are categories
not continuous variables. When considering the extent
of ﬁbrosis, a variable that can be easily quantiﬁed by
image analysis, studies have shown the absence of line-
arity between extent of ﬁbrosis and histological stage
[8,14]. Such an approximation explains why, when con-
sidering only adjacent stages (F1vsF2 or F2vsF3. . .)
AUROC values are unacceptably low, prompting us to
consider the surrogate as an inadequate tool for individ-
ual follow-up [15].
There is an urgent need to pursue the development of
a surrogate for staging ﬁbrosis. Because of the condi-
tional relationship with biopsy, the serum marker might
represent a dead-end. Hopefully, physical imaging will
eventually be reﬁned to an acceptable level of accuracy,
especially for evaluation of early stages of ﬁbrosis.
Indeed, promising results have recently been shown
using elastography with MRI.
Although much eﬀort has been made in evaluation
of ﬁbrosis as a major decision criterion for hepatolo-
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pathologic features present at the same time on liver
biopsy performed for hepatitis C. Fibrosis is not an
autonomous feature, but rather a tissue lesion resulting
from other pathologic mechanisms such as inﬂamma-
tory, degenerative or dystrophic processes leading to
other pathologic mechanisms such as hepatocellular
carcinoma and portal hypertension. In order to provide
relevant information, ﬁbrosis should be viewed in light
of its full histopathologic context. Simultaneous evalu-
ation of necroinﬂammation allows to assess whether
ﬁbrosis is the result of a past event that has stabilized
or even regressed or is an ongoing process that may
continue to worsen. Frequently, biopsy also detects
associated lesions such as steatosis or steatohepatitis
which provide information useful for management
and prognosis of patients with chronic hepatitis C
[16]. Finally, it is noteworthy that, in diseases with a
high prevalence, like hepatitis C, liver biopsy may also
reveal that abnormal liver function tests are related to
an unexpected liver disease in addition to hepatitis C.
Clearly, all this information may inﬂuence patient
management. Therefore, equating chronic liver disease
with the extent of ﬁbrosis alone is an oversimpliﬁcation
that could be useful for physicians but it could also
prove misleading.
After more than 10 years of active investigations,
alternatives to liver biopsy for staging chronic liver dis-
eases have revealed both their strength and weakness.
As emphasized by Mehta et al. ‘‘Novel strategies are
needed to move the ﬁeld forward”. This implies not only
long-term prospective studies using clinical end-points
to validate surrogate markers that might be diﬃcult to
perform especially when addressing validation of mark-
ers for the diagnosis of early stages of ﬁbrosis but also
development of new innovative tools. Whether these
tools will reach a satisfactory level of accuracy prior to
the discovery of highly eﬃcient and innocuous antiviral
treatments remains an open question.
To date, liver biopsy remains the gold/best standard
for accurate staging and grading in chronic hepatitis C
and the major question that remains concerns the
moment at which such an accurate evaluation is needed
in chronic hepatitis C [17].References
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